从BMI分层角度观察中药益糖康对并有IGR的MS的临床疗效

目的:客观评价中药益糖康从体重指数(BMI)分层角度对并有糖调节受损(IGR)的代谢综合征(MS)的临床疗效。方法:采用多中心随机双盲平行对照的试验方法,从符合WHO诊断标准的痰热互结型并有IGR的MS的165例患者,从BMI分层角度进行临床疗效观察。随机分出治疗组患者83例和对照组82例(治疗组予综合治疗并口服益糖康治疗12周;对照组予综合治疗并口服安慰剂12周)。将两组患者分别分为超重组(BMI≥28kg/m2),肥胖组(BMI≥25kg/m2且BMI<28kg/m2),正常组(BMI<25kg/m2)。对患者的空腹血糖、餐后2h血糖、HBA1C、血脂、血压等指标进行临床观察。结果 (:1)痰热互结型并有IGR的MS患者的BMI以25≤BMI<28为主。(2)基础治疗可以改善痰热互结型患者的2hPG、血压和BMI,主要作用于超重组和肥胖组患者。基础治疗虽不能从总体上降低FPG,但却可降低肥胖组的FPG。(3)益糖康治疗可以显著改善BMI、2hPG、TG、TC和血压。其中对于2hPG、TC和血压的治疗作用均体现在超重组和肥胖组。

Clinical Observation on Effect of Yitangkang Treating MS with IGR from the BMI Levels

Objective:To evaluate the clinical effect of Chinese traditional medicine Yitangkang on MS patients of IGR from the perspective of BMI.Method:The study was conducted by the random two-blind control experience in 165 cases of MS patients of IGR diagnosed according to WHO standard from the perspective of BMI.The cases were randomly divided into 2 groups and were treated with oral liquid Yitangkang(group 1)and oral placebo(group 2)respectively and observed for 12 weeks.Afterwards each group was divided into 3 groups,group A(BMI≥28kg/m2),group B(BMI≥25kg/m2 且BMI<28kg/m2 and group C(BMI<25kg/m2)and the observation indexes included the indexes of PG,blood fat and blood pressure.Conclusion:(1)MS patients of IGR with the phlegm heat accumulation mutually are mainly patients with BMI≥25kg/m2且BMI<28kg/m2(2)Foundamental treatment could improve 2hPG,blood pressure and BMI of MS patients of IGR with the phlegm heat accumulation mutually.It made the best use to group A and group B.Though fundamental treatment can’t decrease the index of FPG,it could decrease FPG of group B.(3)The treatment of Yitngkang could significantly improve BMI,2hPG,TG,TC and blood pressure,and it made the best use to group A and group B.